XML 36 R19.htm IDEA: XBRL DOCUMENT
v3.22.0.1

STOCK PLANS | 12 Months Ended
--- | ---
Dec. 31, 2021
STOCK PLANS |
STOCK PLANS | ​ NOTE 10 – STOCK PLANS On April 23, 2015, the shareholders of the Company approved the 2015 Equity and Incentive Compensation Plan ("Employee Plan"). The Employee Plan provides for the granting of options, appreciation rights, restricted shares, restricted stock units and performance-based awards up to an additional 5,400,000 of the Company’s common shares. In addition, on April 23, 2015, the shareholders of the Company approved the 2015 Stock Plan for Non-Employee Directors ("2015 Director Plan"). The 2015 Director Plan provides for the granting of options, restricted shares and restricted stock units up to an additional 300,000 of the Company’s common shares. At December 31, 2021, there were 1,949,554 common shares available for future grant under all plans. Stock Options The following table summarizes stock option activity for the year ended December 31, 2021 under all Plans: ​
​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Weighted
​ | ​ | ​ | ​ | Average
​ | ​ | Number of | ​ | Exercise
​ |  | Options |  | Price
Balance at beginning of year |  | 1,179,761 | ​ | $ | 77.31
Options granted |  | 179,184 | ​ |  | 114.27
Options exercised |  | (287,449) | ​ |  | 66.91
Options canceled | ​ | (630) | ​ | ​ | 59.19
Options forfeited | ​ | (2,642) | ​ | ​ | 89.51
Balance at end of year |  | 1,068,224 | ​ |  | 86.28
Exercisable at end of year |  | 726,972 | ​ |  | 78.93
​ Options granted under both the Employee Plan and its predecessor plans may be outstanding for a maximum of 10 years from the date of grant. The majority of options granted vest ratably over a period of 3 years from the grant date. The exercise prices of all options were equal to the quoted market price of the Company’s common shares at the date of grant. The Company issued shares of common stock from treasury upon all exercises of stock options in 2021. In 2021, all options issued were under the Employee Plan. The Company uses the Black-Scholes option pricing model for estimating fair values of options. In estimating the fair value of options granted, the expected option life is based on the Company’s historical experience. The expected volatility is based on historical volatility. The weighted average assumptions for each of the three years ended December 31 were as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | 2021 |  | 2020 |  | 2019 |
Expected volatility |  | ​ | 28.01 | % | ​ | 25.80 | % | ​ | 25.98 | %
Dividend yield |  | ​ | 2.17 | % | ​ | 2.51 | % | ​ | 2.42 | %
Risk-free interest rate |  | ​ | 0.55 | % | ​ | 1.41 | % | ​ | 2.49 | %
Expected option life (years) |  | ​ | 4.7 |  | ​ | 4.7 |  | ​ | 4.6 | ​
Weighted average fair value per option granted during the year | ​ | $ | 21.70 | ​ | $ | 15.97 | ​ | $ | 17.46 | ​
​ The following table summarizes non-vested stock options for the year ended December 31, 2021: ​
​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Weighted Average
​ | ​ | Number of | ​ | Fair Value at
​ |  | Options |  | Grant Date
Balance at beginning of year |  | 335,835 | ​ | $ | 16.88
Granted |  | 179,184 | ​ |  | 21.70
Vested |  | (170,494) | ​ |  | 17.50
Canceled | ​ | (2,642) | ​ | ​ | 16.12
Forfeited | ​ | (630) | ​ | ​ | 15.56
Balance at end of year |  | 341,253 | ​ |  | 19.11
​ The aggregate intrinsic value of options outstanding and exercisable which would have been received by the optionees had all awards been exercised at December 31, 2021 was $56,814 and $44,009, respectively. The total intrinsic value of awards exercised during 2021, 2020 and 2019 was $20,442, $13,269 and $13,964, respectively. The total fair value of options that vested during 2021, 2020 and 2019 was $2,983, $3,564 and $3,012, respectively. The following table summarizes information about awards outstanding as of December 31, 2021: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Outstanding | ​ | Exercisable
​ | ​ | ​ | ​ | Weighted | ​ | Weighted | ​ | ​ | ​ | Weighted | ​ | Weighted
​ | ​ | Number of | ​ | Average | ​ | Average | ​ | Number of | ​ | Average | ​ | Average
​ | ​ | Stock | ​ | Exercise | ​ | Remaining | ​ | Stock | ​ | Exercise | ​ | Remaining
Exercise Price Range |  | Options |  | Price |  | Life (years) |  | Options |  | Price |  | Life (years)
Under $49.99 |  | 28,287 | ​ | $ | 47.83 |  | 0.90 |  | 28,287 | ​ | $ | 47.83 |  | 0.90
$50.00 - $59.99 |  | 132,756 | ​ |  | 58.12 |  | 4.10 |  | 132,756 | ​ |  | 58.12 |  | 4.10
Over $60.00 |  | 907,181 | ​ |  | 91.60 |  | 6.80 |  | 565,928 | ​ |  | 85.37 |  | 5.70
​ |  | 1,068,224 | ​ | ​ | ​ |  | 6.30 |  | 726,971 | ​ | ​ | ​ |  | 5.20
​ ​ Restricted Stock Units ("RSUs") and Performance Share Units ("PSUs") The following table summarizes RSU and PSU activity for the year ended December 31, 2021 under all Plans: ​
​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Weighted
​ | ​ | ​ | ​ | Average
​ | ​ | Number of | ​ | Grant Date
​ |  | Units |  | Fair Value
Balance at beginning of year |  | 411,489 | ​ | $ | 90.23
Units granted |  | 134,363 | ​ |  | 118.76
Units vested |  | (132,113) | ​ |  | 93.16
Units forfeited |  | (9,913) | ​ |  | 94.70
Balance at end of year |  | 403,826 | ​ |  | 98.65
​ RSUs are valued at the quoted market price on the grant date. The majority of RSUs vest over a period of 3 years. The Company issues shares of common stock from treasury upon the vesting of RSUs and any earned dividend equivalents. Conversion of 29,730 RSUs and PSUs to common shares in 2021 were deferred as part of the 2005 Deferred Compensation Plan for Executives (the "2005 Plan"). As of December 31, 2021, 107,654 RSUs and PSUs, including related dividend equivalents, have been deferred under the 2005 Plan. These units are reflected within dilutive shares in the calculation of earnings per share. In 2021, 103,700 RSUs were issued under the Employee Plan and the 2015 Director Plan. The remaining weighted average vesting period of all non-vested RSUs is 1.4 years as of December 31, 2021. PSUs are valued at the quoted market price on the grant date. PSUs vest over a period of 3 years and are based on the Company’s performance relative to pre-established performance goals. The Company issues common stock from treasury upon the vesting of PSUs and any earned dividend equivalents. In 2021, the Company issued 30,663 PSU’s and has 90,329 PSUs outstanding under the Employee Plan at a weighted average fair value of $97.58 per share. The remaining weighted average vesting period of all non-vested PSUs is 1.1 years as of December 31, 2021. Stock-Based Compensation Expense Expense is recognized for all awards of stock-based compensation by allocating the aggregate grant date fair value over the vesting period. No expense is recognized for any stock options, restricted or deferred shares, RSUs or PSUs ultimately forfeited because recipients fail to meet vesting requirements. Total stock-based compensation expense recognized in the Consolidated Statements of Income for 2021, 2020 and 2019 was $23,787, $15,388 and $16,624, respectively. The related tax benefit for 2021, 2020 and 2019 was $5,988, $3,874 and $4,151, respectively. As of December 31, 2021, total unrecognized stock-based compensation expense related to non-vested stock options, RSUs and PSUs was $19,723, which is expected to be recognized over a weighted average period of approximately 1.8 years. Lincoln Stock Purchase Plan The 1995 Lincoln Stock Purchase Plan provides employees the ability to purchase open market shares on a commission-free basis up to a limit of ten thousand dollars annually. Under this plan, 800,000 shares have been authorized to be purchased. Shares purchased were 9,070 in 2021, 13,667 in 2020 and 13,300 in 2019.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration